Hostname: page-component-7c8c6479df-7qhmt Total loading time: 0 Render date: 2024-03-28T08:34:54.253Z Has data issue: false hasContentIssue false

Post-operative adjuvant chemoradiotherapy with carboplatin and 5-fluorouracil for primary branchiogenic carcinoma

Published online by Cambridge University Press:  08 March 2006

Hideaki Katori
Affiliation:
Department of Otolaryngology, Yokohama City University Medical Center, Yokohama, Japan
Akinori Nozawa
Affiliation:
Department of Pathology, Yokohama City University Medical Center, Yokohama, Japan
Mamoru Tsukuda
Affiliation:
Department of Otolaryngology, Yokohama City University Medical Center, Yokohama, Japan

Abstract

Background: Branchiogenic carcinoma occurs only rarely. A pathologic description and post-operative adjuvant therapy with carboplatin (CBDCA) and daily oral 5-fluorouracil (UFT) are analysed.

Case report: We present the case of a 52-year-old man with a lateral neck mass lesion. A fine-needle aspiration was performed and cytological examination showed class IV disease. The patient underwent excision of the mass and an intra-operative rapid pathological diagnosis of squamous cell carcinoma was made; we then went on to perform neck dissection. The patient received post-operative radiation therapy (total 64 Gy) and chemotherapy (CBDCA 100 mg/week and UFT 300 mg/day). He was followed up for 62 months after surgery without any evidence of recurrence of cancer.

Conclusion: This case satisfies the histological criteria established by Martin and Khafif for a primary branchiogenic carcinoma. The management would be wide surgical excision of the tumour, including neck dissection, followed by adjuvant therapy, such as chemoradiation. As post-operative adjuvant therapy for primary branchiogenic carcinoma, chemoradiotherapy with carboplatin and UFT was a safe and well tolerated regimen.

Type
Research Article
Copyright
© 2005 Royal Society of Medicine Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)